Centene (CNC) Reports Q1 Earnings: What Key Metrics Have to Say

25.04.25 15:30 Uhr

Werte in diesem Artikel
Aktien

53,90 EUR -0,55 EUR -1,01%

Indizes

5.525,2 PKT 40,4 PKT 0,74%

935,5 PKT -8,9 PKT -0,94%

Centene (CNC) reported $46.62 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 15.4%. EPS of $2.90 for the same period compares to $2.26 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $43.47 billion, representing a surprise of +7.24%. The company delivered an EPS surprise of +22.88%, with the consensus EPS estimate being $2.36.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Centene performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Total Medical Health (Benefits) loss Ratios -Total Ratio (HBR): 87.1% versus 87.9% estimated by five analysts on average. Membership Medicaid - High Acuity Medicaid: 1.59 million versus the three-analyst average estimate of 1.59 million. Membership by line of business - Medicaid: 12.96 million compared to the 12.94 million average estimate based on three analysts. SG&A Expense Ratio: 7.9% versus 8.4% estimated by three analysts on average. Revenues- Premium and service revenues: $42.49 billion versus $40.12 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +16.9% change. Revenues- Premium: $41.71 billion compared to the $39.35 billion average estimate based on five analysts. The reported number represents a change of +17.4% year over year. Revenues- Service: $777 million versus $768.54 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -3.8% change. Revenues- Premium tax: $4.13 billion versus the five-analyst average estimate of $3.52 billion. The reported number represents a year-over-year change of +1.5%. Revenues- Premium and service revenues- Commercial: $10.15 billion compared to the $9.04 billion average estimate based on three analysts. The reported number represents a change of +30.9% year over year. Revenues- Premium and service revenues- Medicare: $8.76 billion versus $8.54 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +47.6% change. Revenues- Premium and service revenues- Medicaid: $22.30 billion compared to the $21.45 billion average estimate based on three analysts. The reported number represents a change of +3.9% year over year. Revenues- Premium and service revenues- Other: $1.28 billion versus $1.22 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.6% change. View all Key Company Metrics for Centene here>>>Shares of Centene have returned +2.2% over the past month versus the Zacks S&P 500 composite's -4.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Centene Corporation (CNC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Centene und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Centene

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Centene

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Centene Corp.

Wer­bung

Analysen zu Centene Corp.

DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
20.10.2017Centene OutperformBMO Capital Markets
05.04.2017Centene BuyDeutsche Bank AG
08.02.2017Centene OverweightBarclays Capital
07.02.2017Centene OverweightCantor Fitzgerald
20.06.2016Centene OverweightBarclays Capital
DatumRatingAnalyst
15.06.2015Centene HoldDeutsche Bank AG
15.06.2015Centene Mkt PerformFBR Capital
28.04.2015Centene Mkt PerformFBR Capital
11.02.2015Centene NeutralUBS AG
15.12.2014Centene HoldDeutsche Bank AG
DatumRatingAnalyst
05.12.2006Update Centene Corp.: SellGoldman Sachs
12.06.2006Update Centene Corp.: SellMatrix Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Centene Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen